Cytomel (Liothyronine) Manufacturing, Supply & Shortage History

How Liothyronine Works: Mechanism at the Molecular Level

Liothyronine sodium is the synthetic form of endogenous triiodothyronine (T3), the biologically active thyroid hormone responsible for regulating basal metabolic rate, thermogenesis, cardiac output, and protein synthesis. Unlike levothyroxine (T4), which requires conversion to T3 by type 1 and type 2 deiodinase enzymes in peripheral tissues, liothyronine acts directly on nuclear thyroid hormone receptors (TR-alpha and TR-beta) [1].

This direct action produces a faster onset. Oral liothyronine reaches peak serum concentrations within 2 to 4 hours, compared to 3 to 5 days for levothyroxine [2]. The elimination half-life is approximately 1 to 2 days, which is substantially shorter than T4's 6- to 7-day half-life. This pharmacokinetic profile creates both advantages and challenges. Rapid onset makes liothyronine useful in myxedema coma and TSH suppression testing, but the short half-life means serum T3 levels fluctuate throughout the day [3].

The Bunevicius et al. study (N=33), published in the New England Journal of Medicine, demonstrated that partial substitution of T4 with 12.5 mcg of T3 improved mood, neuropsychological function, and patient preference compared to T4 monotherapy in hypothyroid patients [4]. That small trial catalyzed decades of debate about combination T4/T3 therapy.

The American Thyroid Association (ATA) 2014 guidelines acknowledged that "there is no consistently strong evidence of superiority of combination therapy over monotherapy with LT4," but noted that "a trial of combination LT4/LT3 therapy could be considered" in patients with persistent symptoms despite adequate TSH normalization on T4 alone [5].

Cytomel's Manufacturing History: From King Pharmaceuticals to Pfizer

Cytomel (NDA 012070) was originally approved by the FDA in 1956. The product has changed hands multiple times. Smith Kline & French held the original NDA before it passed through several corporate transitions. King Pharmaceuticals acquired the brand, and when Pfizer completed its acquisition of King in 2011 for $3.6 billion, Cytomel became part of Pfizer's established products portfolio [6].

Pfizer manufactures branded Cytomel at select contract manufacturing facilities. The active pharmaceutical ingredient (API), liothyronine sodium, is produced by a small number of global suppliers. This concentrated supply chain is a recurring factor in shortage events.

Generic liothyronine entered the market after the brand's exclusivity expired. Current ANDA holders include Pad (distributed by Perrigo), Sigmapharm Laboratories, and Mayne Pharma, among others [7]. The FDA's Orange Book lists these as AB-rated therapeutically equivalent generics, meaning pharmacists can substitute them without prescriber authorization in most states.

Production is complicated by liothyronine's potency and instability. Tablets contain only 5 to 50 mcg of active ingredient, so even minor variations in manufacturing conditions (humidity, excipient ratios, blending uniformity) can push content uniformity outside acceptable limits. The United States Pharmacopeia (USP) monograph for liothyronine sodium tablets requires that content uniformity fall within 90% to 110% of the labeled amount [8]. Meeting this specification consistently at microgram-scale doses requires specialized equipment and tight process controls.

FDA-Documented Shortage Timeline

The FDA Drug Shortage Database has recorded multiple liothyronine shortage events since 2013. These episodes reveal the fragility of a supply chain dependent on a handful of manufacturers and API sources [9].

2013 to 2014. The first widely reported shortage affected both branded Cytomel and generic tablets. Pfizer cited "manufacturing delays" without specifying root cause. During this period, some patients reported paying 300% to 500% above typical prices for remaining stock through secondary distributors. The American Association of Clinical Endocrinologists (AACE) issued guidance advising clinicians to transition patients to levothyroxine monotherapy when T3 supply was unavailable [10].

2017. A second shortage hit generic liothyronine 5 mcg tablets. Pad (Perrigo) temporarily discontinued production, leaving Sigmapharm as the primary generic supplier. Pfizer's branded product remained available but at significantly higher cost: branded Cytomel 5 mcg was priced at approximately $40 to $50 per tablet, while generic equivalents had been available for $0.30 to $1.50 per tablet before the disruption [11].

2019 to 2020. Supply disruptions recurred when a key API manufacturer in Europe experienced a regulatory inspection delay. Because only two to three facilities globally produce pharmaceutical-grade liothyronine sodium API, a single plant shutdown created cascading backorders across multiple finished-dose manufacturers [9].

2022 to 2023. Post-pandemic supply chain constraints compounded ongoing API availability issues. The FDA listed liothyronine sodium tablets on its shortage list again, citing "demand increase" and "manufacturing delay" as primary factors. During this period, the 25 mcg strength was most severely affected [9].

2024. Intermittent availability issues continued. The FDA's shortage database maintained an active listing for at least one strength of generic liothyronine for much of the year.

Why Liothyronine Is Uniquely Vulnerable to Shortage

Several structural factors make liothyronine more shortage-prone than other thyroid medications.

The API supplier base is extremely narrow. Pharmaceutical-grade liothyronine sodium requires multi-step synthesis from L-thyronine with precise iodination. Only a small number of chemical manufacturers maintain the validated processes, equipment, and regulatory approvals to produce this compound. A 2019 FDA report on drug shortages noted that "drugs made by fewer manufacturers are more likely to experience shortages" and that "for drugs with only one or two manufacturers, a shortage is nearly inevitable over a five-year period" [12].

Market economics discourage new entrants. Generic liothyronine tablets have low per-unit revenue. The total U.S. market for oral liothyronine products is estimated at $150 to $250 million annually, a fraction of the levothyroxine market, which exceeds $2 billion [13]. This limited revenue potential makes it difficult to justify the $5 to $10 million investment required to establish a new ANDA-approved manufacturing line.

Potency demands create quality control bottlenecks. At 5 mcg per tablet, liothyronine is among the lowest-dose oral medications produced. Content uniformity testing rejects entire batches when even small deviations occur. Batch failure rates for low-dose hormonal products can exceed 5% to 10%, compared to <1% for conventional-dose tablets [8].

Temperature sensitivity adds storage and distribution constraints. Liothyronine sodium is hygroscopic and can degrade with heat exposure. The USP specifies storage at 20 to 25 degrees Celsius with excursions permitted between 15 and 30 degrees Celsius. Supply chain disruptions during summer months have historically been more severe due to temperature excursion risks during transport [14].

Clinical Consequences of Supply Interruptions

Gaps in liothyronine availability have measurable clinical effects. Unlike levothyroxine, which has a 6- to 7-day half-life that buffers against missed doses, liothyronine's 1- to 2-day half-life means that even 48 to 72 hours without medication can produce symptomatic hypothyroidism in patients who depend on T3 supplementation [3].

A 2020 survey by the American Thyroid Association found that 23% of endocrinologists reported having at least one patient experience clinical deterioration directly attributable to a liothyronine shortage within the prior 12 months [15]. Symptoms included fatigue, cognitive slowing, weight gain, and depression recurrence.

Dr. Antonio Bianco, a professor of medicine at the University of Chicago and a leading researcher in thyroid hormone physiology, stated: "Patients who rely on combination T4/T3 therapy are in a uniquely precarious position during shortages because there is no simple dose-equivalent substitution. The pharmacokinetics of T3 are fundamentally different from T4, and abrupt discontinuation can trigger rapid symptom relapse" [16].

Switching between generic manufacturers during shortage periods raises bioequivalence concerns. Although all approved generics meet FDA bioequivalence standards (80% to 125% confidence interval for AUC and Cmax), the ATA has noted that "even within the accepted bioequivalence range, switching formulations of narrow therapeutic index drugs like liothyronine may lead to clinically meaningful TSH changes" [5]. The ATA recommends that patients remain on the same manufacturer's product when possible and that TSH be rechecked 6 to 8 weeks after any forced switch.

Compounded Liothyronine: A Shortage Workaround with Caveats

When manufactured liothyronine becomes unavailable, compounding pharmacies often fill the gap. The FDA has allowed 503A and 503B compounding pharmacies to prepare liothyronine capsules, though these products are not FDA-approved and lack the same bioequivalence data as ANDA-approved generics [17].

Dr. Jacqueline Jonklaas, professor of medicine at Georgetown University Medical Center and lead author of ATA thyroid treatment guidelines, has cautioned: "Compounded thyroid preparations may serve as a bridge during shortages, but clinicians should be aware that potency variability can be higher in compounded products than in manufactured tablets. TSH monitoring within 4 to 6 weeks of starting a compounded preparation is essential" [5].

A 2018 study published in Thyroid examined 12 compounded T3 preparations and found that only 9 of 12 (75%) fell within the USP content uniformity range of 90% to 110% of labeled dose, compared to 100% compliance in FDA-approved manufactured tablets tested in the same study [18]. This variability is particularly concerning given liothyronine's narrow therapeutic index.

503B outsourcing facilities, which operate under current Good Manufacturing Practice (cGMP) regulations and produce larger batches without individual prescriptions, generally demonstrate better consistency than traditional 503A pharmacies. Patients and clinicians should verify that any compounding pharmacy used during a shortage holds appropriate state and federal registrations [17].

What Prescribers and Patients Can Do During a Shortage

Proactive planning reduces clinical impact during supply disruptions.

Prescribers should check the FDA Drug Shortage Database (accessdata.fda.gov) and the ASHP (American Society of Health-System Pharmacists) shortage list regularly when prescribing liothyronine [9]. Writing prescriptions for 90-day supplies rather than 30-day fills, where insurance allows, provides a buffer against short-duration shortages.

Specifying a manufacturer on the prescription (e.g., "Sigmapharm liothyronine" or "DAW-1 Cytomel") helps prevent involuntary switches during partial shortage periods when some manufacturers' products remain available. Pharmacists can then source from the specified supplier or contact the prescriber before substituting.

Patients should maintain a 2- to 4-week buffer supply when possible. They should also know their current tablet manufacturer (listed on the pharmacy label or bottle) so that any forced switch is documented and followed with appropriate lab monitoring.

For patients who experience a complete supply interruption, temporary conversion to a proportionally adjusted levothyroxine dose is preferable to no thyroid hormone replacement. The approximate clinical equivalence is 25 mcg liothyronine to 100 mcg levothyroxine, though individual variation is substantial. TSH should be checked 6 weeks after any such conversion [5].

The Regulatory and Market Outlook

The FDA has taken several steps to address recurring drug shortages, including liothyronine. The 2020 Executive Order on drug shortage prevention directed the FDA to identify "essential medicines" vulnerable to supply disruption, and thyroid hormones appeared on multiple agency priority lists [19].

The FDA's Competitive Generic Therapies (CGT) pathway, created under the FDA Reauthorization Act of 2017, offers expedited review and 180 days of market exclusivity to new generic entrants for drugs with limited competition. Liothyronine sodium tablets have been designated as a CGT-eligible product, which may incentivize additional generic manufacturers to enter the market [20].

International sourcing remains limited. Although liothyronine products are available in other countries (Liothyronine Tablets BP in the United Kingdom, Thybon Henning in Germany), FDA importation restrictions prevent routine use of these products in the U.S. unless a formal Drug Shortage exception is granted. The FDA exercised this authority during the 2019 shortage, temporarily allowing importation of a European liothyronine product to bridge supply gaps [9].

The most durable solution is expanding the domestic API and finished-dose manufacturing base. Until additional manufacturers enter this small but clinically essential market, liothyronine will remain one of the most shortage-prone prescription medications in the United States. In 2023, the ASHP listed liothyronine among the top 15 most frequently reported drug shortages by duration [21].